Stifel lowered the firm’s price target on Nurix Therapeutics (NRIX) to $33 from $35 and keeps a Buy rating on the shares after the company recently reported Q3 results and updated on bexobrutideg registrational plans. The firm’s updated estimates primarily reflect “modestly-higher” FY25 and beyond operating expenses, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- 3 Best Stocks to Buy Now, 10/10/2025, According to Top Analysts
- Nurix Therapeutics price target lowered to $28 from $30 at Oppenheimer
- Nurix Therapeutics price target lowered to $32 from $35 at Piper Sandler
- Nurix Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Closing Bell Movers: Levi Strauss down 8% after results